Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 182

Similar articles for PubMed (Select 24612037)

1.

Inhibition of histone methyltransferase EZH2 depletes leukemia stem cell of mixed lineage leukemia fusion leukemia through upregulation of p16.

Ueda K, Yoshimi A, Kagoya Y, Nishikawa S, Marquez VE, Nakagawa M, Kurokawa M.

Cancer Sci. 2014 May;105(5):512-9. doi: 10.1111/cas.12386. Epub 2014 Mar 30.

PMID:
24612037
2.

Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells.

Nakagawa S, Sakamoto Y, Okabe H, Hayashi H, Hashimoto D, Yokoyama N, Tokunaga R, Sakamoto K, Kuroki H, Mima K, Beppu T, Baba H.

Oncol Rep. 2014 Feb;31(2):983-8. doi: 10.3892/or.2013.2922. Epub 2013 Dec 13.

PMID:
24337160
3.

Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.

Kikuchi J, Takashina T, Kinoshita I, Kikuchi E, Shimizu Y, Sakakibara-Konishi J, Oizumi S, Marquez VE, Nishimura M, Dosaka-Akita H.

Lung Cancer. 2012 Nov;78(2):138-43. doi: 10.1016/j.lungcan.2012.08.003. Epub 2012 Aug 25.

4.

The trithorax protein partner menin acts in tandem with EZH2 to suppress C/EBPα and differentiation in MLL-AF9 leukemia.

Thiel AT, Feng Z, Pant DK, Chodosh LA, Hua X.

Haematologica. 2013 Jun;98(6):918-27. doi: 10.3324/haematol.2012.074195. Epub 2013 Jan 24.

5.

Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.

Fiskus W, Wang Y, Sreekumar A, Buckley KM, Shi H, Jillella A, Ustun C, Rao R, Fernandez P, Chen J, Balusu R, Koul S, Atadja P, Marquez VE, Bhalla KN.

Blood. 2009 Sep 24;114(13):2733-43. doi: 10.1182/blood-2009-03-213496. Epub 2009 Jul 28.

6.

p27kip1 maintains a subset of leukemia stem cells in the quiescent state in murine MLL-leukemia.

Zhang J, Seet CS, Sun C, Li J, You D, Volk A, Breslin P, Li X, Wei W, Qian Z, Zeleznik-Le NJ, Zhang Z, Zhang J.

Mol Oncol. 2013 Dec;7(6):1069-82. doi: 10.1016/j.molonc.2013.07.011. Epub 2013 Aug 20.

7.

Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.

Fiskus W, Pranpat M, Balasis M, Herger B, Rao R, Chinnaiyan A, Atadja P, Bhalla K.

Mol Cancer Ther. 2006 Dec;5(12):3096-104.

8.

MEIS1 regulates an HLF-oxidative stress axis in MLL-fusion gene leukemia.

Roychoudhury J, Clark JP, Gracia-Maldonado G, Unnisa Z, Wunderlich M, Link KA, Dasgupta N, Aronow B, Huang G, Mulloy JC, Kumar AR.

Blood. 2015 Apr 16;125(16):2544-52. doi: 10.1182/blood-2014-09-599258. Epub 2015 Mar 4.

PMID:
25740828
9.

c-Myb is an essential downstream target for homeobox-mediated transformation of hematopoietic cells.

Hess JL, Bittner CB, Zeisig DT, Bach C, Fuchs U, Borkhardt A, Frampton J, Slany RK.

Blood. 2006 Jul 1;108(1):297-304. Epub 2006 Feb 28.

10.

HOXA9 is required for survival in human MLL-rearranged acute leukemias.

Faber J, Krivtsov AV, Stubbs MC, Wright R, Davis TN, van den Heuvel-Eibrink M, Zwaan CM, Kung AL, Armstrong SA.

Blood. 2009 Mar 12;113(11):2375-85. doi: 10.1182/blood-2007-09-113597. Epub 2008 Dec 3.

11.

Loss of AML1/Runx1 accelerates the development of MLL-ENL leukemia through down-regulation of p19ARF.

Nishimoto N, Arai S, Ichikawa M, Nakagawa M, Goyama S, Kumano K, Takahashi T, Kamikubo Y, Imai Y, Kurokawa M.

Blood. 2011 Sep 1;118(9):2541-50. doi: 10.1182/blood-2010-10-315440. Epub 2011 Jul 14.

12.

H3K9me-enhanced DNA hypermethylation of the p16INK4a gene: an epigenetic signature for spontaneous transformation of rat mesenchymal stem cells.

Zheng Y, He L, Wan Y, Song J.

Stem Cells Dev. 2013 Jan 15;22(2):256-67. doi: 10.1089/scd.2012.0172. Epub 2012 Nov 7.

PMID:
22873822
13.

Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization.

Zeisig BB, Milne T, García-Cuéllar MP, Schreiner S, Martin ME, Fuchs U, Borkhardt A, Chanda SK, Walker J, Soden R, Hess JL, Slany RK.

Mol Cell Biol. 2004 Jan;24(2):617-28.

14.

MLL-AF9 and MLL-ENL alter the dynamic association of transcriptional regulators with genes critical for leukemia.

Monroe SC, Jo SY, Sanders DS, Basrur V, Elenitoba-Johnson KS, Slany RK, Hess JL.

Exp Hematol. 2011 Jan;39(1):77-86.e1-5. doi: 10.1016/j.exphem.2010.09.003. Epub 2010 Sep 18.

15.

Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation.

Qi W, Chan H, Teng L, Li L, Chuai S, Zhang R, Zeng J, Li M, Fan H, Lin Y, Gu J, Ardayfio O, Zhang JH, Yan X, Fang J, Mi Y, Zhang M, Zhou T, Feng G, Chen Z, Li G, Yang T, Zhao K, Liu X, Yu Z, Lu CX, Atadja P, Li E.

Proc Natl Acad Sci U S A. 2012 Dec 26;109(52):21360-5. doi: 10.1073/pnas.1210371110. Epub 2012 Dec 10.

16.

Enhancer of zeste homolog 2 is overexpressed and contributes to epigenetic inactivation of p21 and phosphatase and tensin homolog in B-cell acute lymphoblastic leukemia.

Chen J, Li J, Han Q, Sun Z, Wang J, Wang S, Zhao RC.

Exp Biol Med (Maywood). 2012 Sep;237(9):1110-6. Epub 2012 Sep 6.

PMID:
22956625
17.

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.

McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, Liu Y, Graves AP, Della Pietra A 3rd, Diaz E, LaFrance LV, Mellinger M, Duquenne C, Tian X, Kruger RG, McHugh CF, Brandt M, Miller WH, Dhanak D, Verma SK, Tummino PJ, Creasy CL.

Nature. 2012 Dec 6;492(7427):108-12. doi: 10.1038/nature11606. Epub 2012 Oct 10.

PMID:
23051747
18.

Polycomb repressive complex 2 is required for MLL-AF9 leukemia.

Neff T, Sinha AU, Kluk MJ, Zhu N, Khattab MH, Stein L, Xie H, Orkin SH, Armstrong SA.

Proc Natl Acad Sci U S A. 2012 Mar 27;109(13):5028-33. doi: 10.1073/pnas.1202258109. Epub 2012 Mar 6.

19.

Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential.

Wong P, Iwasaki M, Somervaille TC, So CW, Cleary ML.

Genes Dev. 2007 Nov 1;21(21):2762-74. Epub 2007 Oct 17. Erratum in: Genes Dev. 2007 Nov 15;21(22):3017. So, Chai Wai Eric [corrected to So, Chi Wai Eric].

20.

hDOT1L links histone methylation to leukemogenesis.

Okada Y, Feng Q, Lin Y, Jiang Q, Li Y, Coffield VM, Su L, Xu G, Zhang Y.

Cell. 2005 Apr 22;121(2):167-78. Erratum in: Cell. 2005 Jun 3;121(5):809.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk